Home » Merrimack Cancer Drug Fails Mid-Stage Study, Shares Fall
Merrimack Cancer Drug Fails Mid-Stage Study, Shares Fall
Merrimack’s MM-121 cancer drug failed to meet its goal in a mid-stage trial of patients with ovarian cancer.
Reuters
Reuters
Upcoming Events
-
07May
-
14May
-
30May